Rheumatology Advisor—September 7, 2016
In a recent video interview with Rheumatology Advisor, Allan Gibofsky, MD, a rheumatologist at Hospital for Special Surgery, comments on the recent Food and Drug Administration (FDA) approval of adalimumab for noninfectious uveitis.
Dr. Gibofsky explains, "The US Food and Drug Administration (FDA) recently approved adalimumab for noninfectious uveitis, which is primarily an ophthalmologic disease. As a rheumatologist, I do not treat an ophthalmologic disease unless it is a manifestation of a rheumatologic condition ... I think we will see partnerships between nonbiologic-prescribing specialists and biologic-prescribing specialists, but in situations where there are opportunities for shared care and the nonbiologic-prescriber is directly involved in assessing the clinical status of the disease."
To watch the interview, visit RheumatologyAdvisor.com.